sales@intentmarketresearch.com
+1 463-583-2713
RNA Therapeutics Market By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), By Indication (Infectious Diseases, Metabolic Disorders, Oncology, Neurology, Pulmonary Disease, Rare Genetic Diseases), End Use (Hospitals, Clinics, Research Institutions), and By Region; Global Insights & Forecast (2024 – 2030)
As per Intent Market Research, the RNA Therapeutics Market was valued at USD 13.0 billion in 2023 and will surpass USD 18.5 billion by 2030; growing at a CAGR of 5.1% during 2024 - 2030.
The report focuses on estimating the current market potential in terms of the total addressable market for all the segments, sub-segments, and regions. In the process, all the high-growth and upcoming technologies were identified and analyzed to measure their impact on the current and future market. The report also identifies the key stakeholders, their business gaps, and their purchasing behavior. This information is essential for developing effective marketing strategies and creating products or services that meet the needs of the target market. The report also covers a detailed analysis of the competitive landscape which includes major players, their recent developments, growth strategies, product benchmarking, and manufacturing operations among others. Also, brief insights on start-up ecosystem and emerging companies is also included as part of this report.
Report Objectives
The report will help you answer some of the most critical questions in the RNA Therapeutics Market. A few of them are as follows:
- What are the key drivers, restraints, opportunities, and challenges influencing the market growth?
- What are the prevailing technology trends in the RNA Therapeutics Market?
- What is the size of the RNA therapeutics market based on segments, sub-segments, and regions?
- What is the size of different market segments across key regions: North America, Europe, Asia Pacific, Latin America, Middle East & Africa?
- What are the market opportunities for stakeholders after analyzing key market trends?
- Who are the leading market players and what are their market share and core competencies?
- What is the degree of competition in the market and what are the key growth strategies adopted by leading players?
- What is the competitive landscape of the market, including market share analysis, revenue analysis, and a ranking of key players?
Report Scope:
|
Report Features |
Description |
|
Market Size (2023) |
USD 13.0 billion |
|
Forecasted Value (2030) |
USD 18.5 billion |
|
CAGR (2024 – 2030) |
5.1% |
|
Base Year for Estimation |
2023 |
|
Historic Year |
2022 |
|
Forecast Period |
2024 – 2030 |
|
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
|
Segments Covered |
RNA Therapeutics Market By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), By Indication (Infectious Diseases, Metabolic Disorders, Oncology, Neurology, Pulmonary Disease, Rare Genetic Diseases), End Use (Hospitals, Clinics, Research Institutions) |
|
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Spain, Italy & Rest of Europe), Asia Pacific (China, Japan, South Korea, India, and Rest of Asia Pacific), Latin America (Brazil, Argentina, & Rest of Latin America), Middle East & Africa (Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA) |
|
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
|
1.Introduction |
|
1.1.Market Definition |
|
1.2.Scope of the Study |
|
1.3.Research Assumptions |
|
1.4.Study Limitations |
|
2.Research Methodology |
|
2.1.Research Approach |
|
2.1.1.Top-Down Method |
|
2.1.2.Bottom-Up Method |
|
2.1.3.Factor Impact Analysis |
|
2.2.Insights & Data Collection Process |
|
2.2.1.Secondary Research |
|
2.2.2.Primary Research |
|
2.3.Data Mining Process |
|
2.3.1.Data Analysis |
|
2.3.2.Data Validation and Revalidation |
|
2.3.3.Data Triangulation |
|
3.Executive Summary |
|
3.1.Major Markets & Segments |
|
3.2.Highest Growing Regions and Respective Countries |
|
3.3.Impact of Growth Drivers & Inhibitors |
|
3.4.Regulatory Overview by Country |
|
4.RNA Therapeutics Market, by Product (Market Size & Forecast: USD Million, 2022 – 2030) |
|
4.1.Drugs |
|
4.2.Vaccines |
|
5.RNA Therapeutics Market, by Type (Market Size & Forecast: USD Million, 2022 – 2030) |
|
5.1.Antisense Oligonucleotides |
|
5.2.RNA Interference |
|
5.3.mRNA Therapeutics |
|
6.RNA Therapeutics Market, by Indication (Market Size & Forecast: USD Million, 2022 – 2030) |
|
6.1.Rare Genetic Diseases |
|
6.2.Oncology |
|
6.3.Neurology |
|
6.4.Infectious Diseases |
|
6.5.Metabolic Disorders |
|
6.6.Pulmonary Disease |
|
7.RNA Therapeutics Market, by End Use (Market Size & Forecast: USD Million, 2022 – 2030) |
|
7.1.Hospitals |
|
7.2.Clinics |
|
7.3.Research Institutions |
|
8.Regional Analysis (Market Size & Forecast: USD Million, 2022 – 2030) |
|
8.1.Regional Overview |
|
8.2.North America |
|
8.2.1.Regional Trends & Growth Drivers |
|
8.2.2.Barriers & Challenges |
|
8.2.3.Opportunities |
|
8.2.4.Factor Impact Analysis |
|
8.2.5.Technology Trends |
|
8.2.6.North America RNA Therapeutics Market, by Product |
|
8.2.8.North America RNA Therapeutics Market, by Type |
|
8.2.8.North America RNA Therapeutics Market, by Indication |
|
8.2.9.North America RNA Therapeutics Market, by End use |
|
*Similar segmentation will be provided at each regional level |
|
8.3.By Country |
|
8.3.1.US |
|
8.3.1.1.US RNA Therapeutics Market, by Product |
|
8.3.1.2.US RNA Therapeutics Market, by Type |
|
8.3.1.3.US RNA Therapeutics Market, by Indication |
|
8.3.1.4.US RNA Therapeutics Market, by End use |
|
8.3.2.Canada |
|
8.3.3.Mexico |
|
*Similar segmentation will be provided at each country level |
|
8.4.Europe |
|
8.5.APAC |
|
8.6.Latin America |
|
8.8.Middle East & Africa |
|
9.Competitive Landscape |
|
9.1.Overview of the Key Players |
|
9.2.Competitive Ecosystem |
|
9.2.1.Platform Manufacturers |
|
9.2.2.Subsystem Manufacturers |
|
9.2.3.Service Providers |
|
9.2.4.Software Providers |
|
9.3.Company Share Analysis |
|
9.4.Company Benchmarking Matrix |
|
9.4.1.Strategic Overview |
|
9.4.2.Product Innovations |
|
9.5.Start-up Ecosystem |
|
9.6.Strategic Competitive Insights/ Customer Imperatives |
|
9.7.ESG Matrix/ Sustainability Matrix |
|
9.9.Manufacturing Network |
|
9.9.1.Locations |
|
9.9.2.Supply Chain and Logistics |
|
9.9.3.Product Flexibility/Customization |
|
9.9.4.Digital Transformation and Connectivity |
|
9.9.5.Environmental and Regulatory Compliance |
|
9.9.Technology Readiness Level Matrix |
|
9.10.Technology Maturity Curve |
|
9.11.Buying Criteria |
|
10.Company Profiles |
|
10.1.Moderna, Inc. |
|
10.1.1.Company Overview |
|
10.1.2.Company Financials |
|
10.1.3.Product/Service Portfolio |
|
10.1.4.Recent Developments |
|
10.1.5.IMR Analysis |
|
*Similar information will be provided for other companies |
|
10.2.Sanofi |
|
10.3.Novartis |
|
10.4.BioNTech |
|
10.5.CRISPR Therapeutics |
|
10.6.Ionis Pharmaceuticals |
|
10.7.Silence Therapeutics |
|
10.8.Sirnaomics |
|
10.10.Arbutus Biopharma |
|
10.10.Astellas Pharma |
|
11.Appendix |
Let us connect with you TOC
A comprehensive market research approach was employed to gather and analyze data on the RNA Therapeutics Market. In the process, the analysis was also done to estimate the parent market and relevant adjacencies to measure the impact of them on the RNA Therapeutics Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
.jpg)
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the RNA Therapeutics ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Estimation
A combination of top-down and bottom-up approaches was utilized to estimate the overall size of the RNA therapeutics market. These methods were also employed to estimate the size of various subsegments within the market. The market size estimation methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
.jpg)
Data Triangulation
To ensure the accuracy and reliability of the market size estimates, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size estimates.
Available Formats
Buy Now